Takeda grows in gene therapies again with $2bn Code Bio deal

Science Molecule, Molecular DNA Model Structure, business teamwork conceptMolecular, DNA and atom model in science research labMolecular, DNA and atom model in science research lab setting in studio.

Takeda has forged another alliance as it continues a push into gene therapy, agreeing a deal worth up to $2 billion with Code Biotherapeutics for opt-in rights to four candidates for rare diseases.

The Japanese drugmaker will get access to Code Bio's 3DNA non-viral genetic medicine delivery platform, initially for a liver-directed programme, and is also interested in deploying the technology for central nervous system disorders.

The deal is mostly back-loaded, with "double-digit million" dollars in upfront payment, research funding and milestone payments.

Interest in non-viral methods of delivering gene therapies has been growing in the face of current scrutiny of the safety of viral vectors like adeno-associated viruses (AAV), with a number of clinical programmes based on AAV under clinical holds imposed by the FDA.

Code Bio's 3DNA vectors are based on pieces of synthetic DNA linked together to form a scaffold that can carry a larger gene sequence than viral vectors, and according to the biotech don't trigger an immune response which might cause side effects or limit the potential for re-dosing.

Those properties were referenced by Takeda's head of rare diseases R&D – Madhu Natarajan – who said in a statement that the partnership "will hopefully enable us to develop re-dosable and durable gene therapies that will be superior to current approaches."

Takeda is the first pharma company to publicise an alliance with Philadelphia-based Code Bio, which launched officially last April with $10 million in seed financing.

The Japanese company has been on a big pipeline-building push in the last couple of years, signing a string of deals with rare diseases and gene and cell therapies featuring prominently.

Last October it signed a $3.6 billion agreement with Poseida Therapeutics on gene therapies for six to eight programmes across liver and haematologic diseases, and another with Selecta Biosciences targeting lysosomal storage disorders valued at $1.1 billion-plus.

In the same month it also bought UK cancer cell therapy specialist GammaDelta, adding to earlier acquisitions of TiGenix and T-cell engager company Maverick Therapeutics.

23 February, 2022